## RFP QUESTIONS AND ANSWERS

<table>
<thead>
<tr>
<th>RFP Q&amp;A Number</th>
<th>831100-RFP-01</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Title</td>
<td>Electronic Health Record (EHR) Company for HPV Vaccination Study</td>
</tr>
<tr>
<td>Application Deadline</td>
<td>February 9, 2018</td>
</tr>
<tr>
<td>Proposals must be</td>
<td><a href="mailto:357RFP@aap.org">357RFP@aap.org</a></td>
</tr>
<tr>
<td>Questions about this</td>
<td>January 19, 2018</td>
</tr>
<tr>
<td>Responses to questions</td>
<td>February 2, 2018</td>
</tr>
</tbody>
</table>

### QUESTIONS AND ANSWERS

**Q1:** How long must a practice be using the EHR to be eligible for the study?

**A1:** The practice must have had the EHR in place for a minimum of a year.

**Q2:** Are there any eligibility requirements in terms of practice size?

**A2:** No, there are no eligibility requirements regarding practice size.

**Q3:** Specifically, what sort of intervention will participating practices be providing?

**A3:** For this study, the practices will be the direct recipients of the study intervention. Specifically, clinicians and practice staff will engage in distance learning with feedback and text-based elements. There will be three distinct training modules focused on different aspects of practice behavior around delivery of HPV vaccine (activities described further in second set of bullets, below). In terms of responsibilities, all practices must:

- Agree to participate in the study for approximately 28 months
- Agree to not participate in any other HPV-related Quality Improvement or Research Projects throughout the duration of the study
- Complete PROS intake forms
- Complete a baseline survey
- If needed, complete local IRB procedures
- Enter into a Data Use Agreement with the AAP

If the practice is in the intervention group, over the course of approximately 21 months, they will be asked to (all activities and time estimates are approximate):

- Participate in approximately 4 online virtual training sessions (~15 minutes each) and 3 office practice sessions (~15 min each)
- Receive tips via text message each week
- Review 7 feedback reports along with videos explaining the reports (~5-10 min each)
- Agree to have practice staff receive training on providing vaccine prompts to providers
- Have all providers complete 4 short online surveys (~5-15 min each) and evaluate each training session (~1-2 min each)
- Have one provider complete online surveys about each month (~5-15 minutes)
Practices in the control group will, over the course of 7 months in later months of the study, complete the same intervention as the control (some activities will be abbreviated). In summary, all participants will have the opportunity experience and benefit from the intervention activities.

Q4: How many providers can participate within each participating practice?

A4: At least one clinician per practice – however, we encourage as many as possible to participate!

Q5: Will they need to attend any offsite training?

A5: No offsite training is needed. All training will be provided virtually.

Q6: In terms of responsibilities, all practices must:

* Agree to not participate in any other HPV-related Quality Improvement or Research Projects throughout the duration of the study.

Many practices participate in a "Health in Focus" quality improvement program through Merck which is related to HPV vaccination. With this program, if practices achieve improvement in HPV vaccination rates, they benefit from significant rebates on vaccine purchases. Will participation in this study mean that practices won’t be able to participate in this Merck rebate program?

A6: No, participation in the "Health in Focus" program would not alone disqualify the practice from participating.